There are no specific legal restrictions on the formulation or dosage form of medicinal cannabis products exempt from authorisation (magistral preparations). This would run counter to the purpose of the prescription of such preparations, which are also intended precisely for experimental use in patients refractory to standard treatments. Such restrictions would interfere with physicians’ therapeutic freedom.
For reasons of therapeutic product law, however, finished medicinal cannabis products must always have a known active substance content and a defined chemical profile, enabling physicians to control the dosing process, as for any other treatment. Further information on this topic can be found in the Position paper issued by the Association of Cantonal Pharmacists.